Cardiff Oncology, Inc. (CRDF)
Nasdaq: CRDF · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2003
Who owns Cardiff Oncology, Inc.
As filed with the SECHolders of 5% or more
0
No Schedule 13D or 13G naming this company is on file.
Directors and officers
11
report now, of 26 people on the record since 2012. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 0 named at left.
Holders of 5% or moreshare of the class, as filed
Pfizer Inc.
SCHEDULE 13G/A · filed Feb 12, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 27, 2026 · Common Stock · reported falling below 5%, from 5.8% in Apr 23, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 5.6% in Jul 29, 2025
Commodore Capital LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock · reported falling below 5%, from 8.1% in Dec 17, 2024
What CRDF reports owning in othersstakes of 5% or more, and other ties
Cardiff Oncology, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
4purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$1.1Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 31 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Mohindru Mani | Chief Executive Officer | 0 | $0 | 0 | 2 | $100,000 |
| Pace Gary W | director | 0 | $0 | 0 | 2 | $1.0M |